Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
90.3% of Rallybio shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Rapport Therapeutics and Rallybio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapport Therapeutics | 1 | 0 | 9 | 1 | 2.91 |
| Rallybio | 1 | 0 | 0 | 0 | 1.00 |
Volatility & Risk
Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.
Profitability
This table compares Rapport Therapeutics and Rallybio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapport Therapeutics | N/A | -24.78% | -23.44% |
| Rallybio | -911.07% | -55.79% | -51.48% |
Valuation & Earnings
This table compares Rapport Therapeutics and Rallybio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapport Therapeutics | N/A | N/A | -$111.48 million | ($2.60) | -14.97 |
| Rallybio | $860,000.00 | 96.82 | -$8.98 million | ($4.34) | -3.62 |
Rallybio has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Summary
Rapport Therapeutics beats Rallybio on 10 of the 14 factors compared between the two stocks.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
